Update shared on 29 Nov 2025
Fair value Decreased 3.59%Analysts have adjusted their price target for AbCellera Biologics slightly downward from $10.20 to $9.83 per share. This change reflects more conservative expectations around future revenue growth and profit margins.
What's in the News
- AbCellera Biologics will change its independent registered public accounting firm from KPMG LLP to Ernst & Young LLP for the fiscal year ending December 31, 2026 (Key Developments).
- The dismissal of KPMG LLP as auditor was not due to any disagreements regarding accounting principles, financial statement disclosures, or auditing procedures (Key Developments).
- The company’s audit firm change follows a formal review and tender process conducted by the Audit Committee earlier in the year (Key Developments).
- The transition to Ernst & Young LLP is pending completion of standard client acceptance and independence procedures. The change will be effective after KPMG completes the fiscal year 2025 audit (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has been reduced slightly, moving from $10.20 to $9.83 per share.
- Discount Rate has risen marginally, changing from 7.58% to 7.60%.
- Revenue Growth expectations have fallen, adjusting from 53.87% to 51.99%.
- Net Profit Margin projections have edged down, decreasing from 15.70% to 15.51%.
- Future P/E ratio estimates have decreased slightly, going from 195.53x to 192.96x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.